New scan could reveal how well your immune system fights cancer
NCT ID NCT05259709
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests an experimental imaging agent (89Zr-DFO-REGN5054) that may help visualize immune cells called CD8+ T cells in tumors. About 50 people with advanced solid cancers will receive the imaging agent along with the immunotherapy drug cemiplimab. The main goal is to check safety and see if the scan can show how the immune system responds to treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 89Zr-DFO-REGN5054 (imaging agent) and cemiplimab (cancer drug)
- What this could lead to
- If successful, this imaging method could help doctors see how well the immune system is attacking tumors, guiding better use of immunotherapy.
- What could go wrong
- This is an early Phase 1 study with only 50 participants, so the imaging agent may not work as hoped or could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UMC Groningen
RECRUITINGGroningen, 9700 RB, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a new drug shrink Hard-to-Treat tumors?
- Can a Custom-Made immune cell vaccine turn the tide against solid tumors?